Apellis Pharmaceuticals, Inc. (APLS) Tops Q2 EPS by 15c
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Join SI Premium – FREE
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q2 EPS of ($0.33), $0.15 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $178.49 million versus the consensus estimate of $186.76 million.
For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rockstar Energy founder seeks CEO role at Celsius Holdings
- bioAffinity (BIAF) Tops Q2 EPS by 146c
- King Pharmaceuticals (KG) Misses Q2 EPS by 103c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
